Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with pseudophakic CME defined as central retinal thickness (CRT)\>300 microns, presence of intraretinal cysts on optical coherence tomography (OCT) and visual acuity \<=20/32 with petaloid leakage on fluorescein angiogram and late leakage at the disc~2. Diagnosed with recalcitrant CME, defined as less than a 15% decrease in CRT after at least 6 weeks of topical non-steroidal anti-inflammatory drug~3. Has had cataract surgery in the study eye with posterior chamber or anterior chamber intraocular lens implantation~4. Willing and able to comply with clinic visits and study-related procedures~5. Provide signed informed consent~Exclusion Criteria:~1. Retinal diseases (including diabetic retinopathy, retinal vein or artery occlusion, neovascular age-related macular degeneration, radiation retinopathy, vitreomacular traction, epiretinal membrane).~2. Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye.~3. Active infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye.~4. Prior treatment with sub-Tenon's or intravitreal steroids.~5. Prior treatment with an intravitreal anti-vascular endothelial growth factor (VEGF) agent in the study eye or systemic administration of anti-VEGF.~6. Use of topical prostaglandin analogues or pilocarpine.~7. Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with glaucoma medications.~8. Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye.~9. Vision loss in the study eye, determined by the investigator to be from a cause other than CME, e.g. optic neuropathy, end-stage glaucoma.~10. Any significant media opacity including vitreous hemorrhage or corneal scarring.~11. Fluorescein dye allergy or intolerance~12. Allergy to aflibercept or any of the components~13. Cerebrovascular accident or myocardial infarction within 1 year of the screening visit.~14. Pregnant or breast-feeding women~15. Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception starting at least 2 menstrual cycles prior to the baseline visit, during the study and in the 3 months immediately following the last dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subconjunctival aflibercept (Type: EXPERIMENTAL): Subconjunctival aflibercept 2 milligrams (mg) /0.05 milliliters (mL) administered at baseline visit and possibly again at Month 1 visit depending on initial response.

Based on this trial design, predict the completion outcome and termination type (if applicable).